Table 1.
Anti-ZIKV antibody response in BALB/c mice inoculated with ZIKBeHMR-2.
| Immune Sera | |||
|---|---|---|---|
| Controls 1 | Weeks | Anti-ZIKV.rEDIII 2 | PRNT503 |
| PBS/FBS | 4 | <50 | <50 |
| Cell supernatant | 4 | <50 | <50 |
| Inactivated ZIKV | 4 | <50 | <50 |
| ZIKBeHMR-2 4 | |||
| 1st dose | 4 | 1083 (844–1391) | 529 (385–726) |
| 2nd dose | 10 | 6174 (3733–10212) | 6032 (4039–9009) |
1 Pooled sera from a group of BALB/c mice (n = 5) inoculated with one dose of vehicle PBS/FBS (PBS/FBS) or Vero cell supernatant (Cell supernatant). Pooled sera from a group of BALB/c (n = 5) inoculated with one dose of heat-inactivated ZIKBeHMR-2 virus (equivalent dose of 5 log PFU) (inactivated ZIKV). Serum samples were collected 4 weeks post-inoculation. 2 The anti-ZIKV E antibody titers in pooled immune sera were determined by indirect ELISA using ZIKV rEDIII as capture antigen. The geometrical means with 95% Confidence Interval (C.I.) of anti-EDIII IgG titer values from three independent experiments are given. 3Neutralizing activity of pooled immune sera using a conventional PRNT on Vero cells. PRNT50: the highest serum dilution that reduced the number of PFU of ZIKBeHMR-2 by at least 50%. The geometrical means with 95% Confidence Interval (C.I.) of PRNT50 values from three independent experiments are given. 4Immune sera were collected from groups of adults BALB/c (n = 5) that received one or two doses of 5 log PFU of ZIKBeHMR-2 with an interval of 6 weeks. Serum samples were collected 4 (prime) or 10 weeks (prime and boost) post-inoculation.